In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Ex Input:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Office of Strategic Services 
Congressional Gold Medal Act''.

SEC. 2. FINDINGS.

    The Congress finds the following:
            (1) The Office of Strategic Services (OSS) was America's 
        first effort to implement a system of strategic intelligence 
        during World War II and provided the basis for the modern-day 
        American intelligence and special operations communities. The 
        U.S. Special Operations Command and the National Clandestine 
        Service chose the OSS spearhead as their insignias.
            (2) OSS founder General William J. Donovan is the only 
        person in American history to receive our Nation's four highest 
        decorations, including the Medal of Honor. Upon learning of his 
        death in 1959, President Eisenhower called General Donovan the 
        ``last hero''. In addition to founding and leading the OSS, 
        General Donovan was also selected by President Roosevelt, who 
        called him his ``secret legs'', as an emissary to Great Britain 
        and continental Europe before the United States entered World 
        War II.
            (3) All the military branches during World War II 
        contributed personnel to the OSS. The present-day Special 
        Operations Forces trace their lineage to the OSS. Its Maritime 
        Unit was a precursor to the U.S. Navy SEALs. The OSS 
        Operational Groups and Jedburghs were forerunners to U.S. Army 
        Special Forces. The 801st/492nd Bombardment Group 
        (``Carpetbaggers'') were progenitors to the Air Force Special 
        Operations Command. The Marines who served in the OSS, 
        including the actor Sterling Hayden (a Silver Star recipient), 
        Col. William Eddy (a Distinguished Service Cross recipient who 
        was described as the ``nearest thing the United States has had 
        to a Lawrence of Arabia''), and Col. Peter Ortiz (a two-time 
        Navy Cross recipient), were predecessors to the Marine Special 
        Operations Command. U.S. Coast Guard personnel were recruited 
        for the Maritime Unit and its Operational Swimmer Group.
            (4) The OSS organized, trained, supplied, and fought with 
        resistance organizations throughout Europe and Asia that played 
        an important role in America's victory during World War II. 
        General Eisenhower credited the OSS's covert contribution in 
        France to the equivalent to having an extra military division. 
        General Eisenhower told General Donovan that if it did nothing 
        else, the photographic reconnaissance conducted by the OSS 
        prior to the D-Day Invasion justified its creation.
            (5) Four future directors of central intelligence served as 
        OSS officers: William Casey, William Colby, Allen Dulles, and 
        Richard Helms.
            (6) Women comprised more than one-third of OSS personnel 
        and played a critical role in the organization. They included 
        Virginia Hall, the only civilian female to receive a 
        Distinguished Service Cross in World War II, and Julia Child.
            (7) OSS recruited Fritz Kolbe, a German diplomat who became 
        America's most important spy against the Nazis in World War II.
            (8) America's leading scientists and scholars served in the 
        OSS Research and Analysis Branch, including Ralph Bunche, the 
        first African-American to receive the Nobel Peace Prize; 
        Pulitzer Prize-winning historian Arthur Schlesinger, Jr.; 
        Supreme Court Justice Arthur Goldberg; Sherman Kent; John King 
        Fairbank; and Walt Rostow. Its ranks included seven future 
        presidents of the American Historical Association, five of the 
        American Economic Association, and two Nobel laureates.
            (9) The U.S. Department of State's Bureau of Intelligence 
        and Research traces its creation to the OSS Research and 
        Analysis Branch.
            (10) James Donovan, who was portrayed by Tom Hanks in the 
        Steven Spielberg movie ``Bridge of Spies'' and negotiated the 
        release of U-2 pilot Francis Gary Powers, served as General 
        Counsel of the OSS.
            (11) The OSS invented and employed new technology through 
        its Research and Development Branch, inventing new weapons and 
        revolutionary communications equipment. Dr. Christian 
        Lambertsen invented the first underwater rebreathing apparatus 
        that was first utilized by the OSS and is known today as SCUBA.
            (12) OSS Detachment 101 operated in Burma and pioneered the 
        art of unconventional warfare. It was the first United States 
        unit to deploy a large guerrilla army deep in enemy territory. 
        It has been credited with the highest kill/loss ratio for any 
        infantry-type unit in American military history and was awarded 
        a Presidential Unit Citation.
            (13) Its X-2 branch pioneered counterintelligence with the 
        British and established the modern counterintelligence 
        community. The network of contacts built by the OSS with 
        foreign intelligence services led to enduring Cold War 
        alliances.
            (14) Operation Torch, the Allied invasion of French North 
        Africa in November 1942, was aided by the networks established 
        and information acquired by the OSS to guide Allied landings.
            (15) OSS Operation Halyard rescued more than 500 downed 
        airmen trapped behind enemy lines in Yugoslavia, one of the 
        most daring and successful rescue operations of World War II.
            (16) OSS ``Mercy Missions'' at the end of World War II 
        saved the lives of thousands of Allied prisoners of war whom it 
        was feared would be murdered by the Japanese.
            (17) The handful of surviving men and women of the OSS whom 
        General Donovan said performed ``some of the bravest acts of 
        the war'' are members of the ``Greatest Generation''. They have 
        never been collectively recognized for their heroic and 
        pioneering service in World War II.

SEC. 3. CONGRESSIONAL GOLD MEDAL.

    (a) Presentation Authorized.--The Speaker of the House of 
Representatives and the President pro tempore of the Senate shall make 
appropriate arrangements for the presentation, on behalf of the 
Congress, of a gold medal of appropriate design in commemoration to the 
members of the Office of Strategic Services (OSS), in recognition of 
their superior service and major contributions during World War II.
    (b) Design and Striking.--For purposes of the presentation referred 
to in subsection (a), the Secretary of the Treasury (referred to in 
this Act as the ``Secretary'') shall strike a gold medal with suitable 
emblems, devices, and inscriptions, to be determined by the Secretary.
    (c) Smithsonian Institution.--
            (1) In general.--Following the award of the gold medal in 
        commemoration to the members of the Office of Strategic 
        Services under subsection (a), the gold medal shall be given to 
        the Smithsonian Institution, where it will be displayed as 
        appropriate and made available for research.
            (2) Sense of congress.--It is the sense of Congress that 
        the Smithsonian Institution should make the gold medal received 
        under paragraph (1) available for display elsewhere, 
        particularly at other appropriate locations associated with the 
        Office of Strategic Services.

SEC. 4. DUPLICATE MEDALS.

    The Secretary may strike and sell duplicates in bronze of the gold 
medal struck pursuant to section 3 under such regulations as the 
Secretary may prescribe, at a price sufficient to cover the cost 
thereof, including labor, materials, dies, use of machinery, and 
overhead expenses, and the cost of the gold medal.

SEC. 5. STATUS OF MEDALS.

    (a) National Medals.--The medals struck pursuant to this Act are 
national medals for purposes of chapter 51 of title 31, United States 
Code.
    (b) Numismatic Items.--For purposes of section 5134 of title 31, 
United States Code, all medals struck under this Act shall be 
considered to be numismatic items.

Ex Output:
Office of Strategic Services Congressional Gold Medal Act  This bill requires the Speaker of the House of Representatives and the President pro tempore of the Senate to arrange for the presentation of a Congressional Gold Medal to the members of the Office of Strategic Services in recognition of their service and contributions during World War II.


Ex Input:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Opioid Use Disorder Treatment 
Expansion and Modernization Act''.

SEC. 2. FINDING.

    The Congress finds that opioid use disorder has become a public 
health epidemic that must be addressed by increasing awareness and 
access to all treatment options for opioid use disorder, overdose 
reversal, and relapse prevention.

SEC. 3. OPIOID USE DISORDER TREATMENT MODERNIZATION.

    (a) In General.--Section 303(g)(2) of the Controlled Substances Act 
(21 U.S.C. 823(g)(2)) is amended--
            (1) in subparagraph (B), by striking clauses (i), (ii), and 
        (iii) and inserting the following:
            ``(i) The practitioner is a qualifying practitioner (as 
        defined in subparagraph (G)).
            ``(ii) With respect to patients to whom the practitioner 
        will provide such drugs or combinations of drugs, the 
        practitioner has the capacity to provide directly, by referral, 
        or in such other manner as determined by the Secretary--
                    ``(I) all schedule III, IV, and V drugs, as well as 
                unscheduled medications approved by the Food and Drug 
                Administration, for the treatment of opioid use 
                disorder, including such drugs and medications for 
                maintenance, detoxification, overdose reversal, and 
                relapse prevention, as available; and
                    ``(II) appropriate counseling and other appropriate 
                ancillary services.
            ``(iii)(I) The total number of such patients of the 
        practitioner at any one time will not exceed the applicable 
        number. Except as provided in subclause (II), the applicable 
        number is 30.
            ``(II) The applicable number is 100 if, not sooner than 1 
        year after the date on which the practitioner submitted the 
        initial notification, the practitioner submits a second 
        notification to the Secretary of the need and intent of the 
        practitioner to treat up to 100 patients.
            ``(III) The Secretary may by regulation change such total 
        number.
            ``(IV) The Secretary may exclude from the applicable number 
        patients to whom such drugs or combinations of drugs are 
        directly administered by the qualifying practitioner in the 
        office setting.
            ``(iv) If the Secretary by regulation increases the total 
        number of patients which a qualifying practitioner is permitted 
        to treat pursuant to clause (iii)(II), the Secretary shall 
        require such a practitioner to obtain a written agreement from 
        each patient, including the patient's signature, that the 
        patient--
                    ``(I) will receive an initial assessment and 
                treatment plan and periodic assessments and treatment 
                plans thereafter;
                    ``(II) will be subject to medication adherence and 
                substance use monitoring;
                    ``(III) understands available treatment options, 
                including all drugs approved by the Food and Drug 
                Administration for the treatment of opioid use 
                disorder, including their potential risks and benefits; 
                and
                    ``(IV) understands that receiving regular 
                counseling services is critical to recovery.
            ``(v) The practitioner will comply with the reporting 
        requirements of subparagraph (D)(i)(IV).'';
            (2) in subparagraph (D)--
                    (A) in clause (i), by adding at the end the 
                following:
            ``(IV) The practitioner reports to the Secretary, at such 
        times and in such manner as specified by the Secretary, such 
        information and assurances as the Secretary determines 
        necessary to assess whether the practitioner continues to meet 
        the requirements for a waiver under this paragraph.'';
                    (B) in clause (ii), by striking ``Upon receiving a 
                notification under subparagraph (B)'' and inserting 
                ``Upon receiving a determination from the Secretary 
                under clause (iii) finding that a practitioner meets 
                all requirements for a waiver under subparagraph (B)''; 
                and
                    (C) in clause (iii)--
                            (i) by inserting ``and shall forward such 
                        determination to the Attorney General'' before 
                        the period at the end of the first sentence; 
                        and
                            (ii) by striking ``physician'' and 
                        inserting ``practitioner'';
            (3) in subparagraph (G)--
                    (A) by amending clause (ii)(IV) to read as follows:
                    ``(IV) The physician has, with respect to the 
                treatment and management of opiate-dependent patients, 
                completed not less than 8 hours of training (through 
                classroom situations, seminars at professional society 
                meetings, electronic communications, or otherwise) that 
                is provided by the American Society of Addiction 
                Medicine, the American Academy of Addiction Psychiatry, 
                the American Medical Association, the American 
                Osteopathic Association, the American Psychiatric 
                Association, or any other organization that the 
                Secretary determines is appropriate for purposes of 
                this subclause. Such training shall address--
                            ``(aa) opioid maintenance and 
                        detoxification;
                            ``(bb) appropriate clinical use of all 
                        drugs approved by the Food and Drug 
                        Administration for the treatment of opioid use 
                        disorder;
                            ``(cc) initial and periodic patient 
                        assessments (including substance use 
                        monitoring);
                            ``(dd) individualized treatment planning; 
                        overdose reversal; relapse prevention;
                            ``(ee) counseling and recovery support 
                        services;
                            ``(ff) staffing roles and considerations;
                            ``(gg) diversion control; and
                            ``(hh) other best practices, as identified 
                        by the Secretary.''; and
                    (B) by adding at the end the following:
            ``(iii) The term `qualifying practitioner' means--
                    ``(I) a qualifying physician, as defined in clause 
                (ii); or
                    ``(II) during the period beginning on the date of 
                the enactment of the Opioid Use Disorder Treatment 
                Expansion and Modernization Act and ending on the date 
                that is 3 years after such date of enactment, a 
                qualifying other practitioner, as defined in clause 
                (iv).
            ``(iv) The term `qualifying other practitioner' means a 
        nurse practitioner or physician assistant who satisfies each of 
        the following:
                    ``(I) The nurse practitioner or physician assistant 
                is licensed under State law to prescribe schedule III, 
                IV, or V medications for the treatment of pain.
                    ``(II) The nurse practitioner or physician 
                assistant satisfies one or more of the following:
                            ``(aa) Has completed not fewer than 24 
                        hours of initial training addressing each of 
                        the topics listed in clause (ii)(IV) (through 
                        classroom situations, seminars at professional 
                        society meetings, electronic communications, or 
                        otherwise) provided by the American Society of 
                        Addiction Medicine, the American Academy of 
                        Addiction Psychiatry, the American Medical 
                        Association, the American Osteopathic 
                        Association, the American Nurses Credentialing 
                        Center, the American Psychiatric Association, 
                        the American Association of Nurse 
                        Practitioners, the American Academy of 
                        Physician Assistants, or any other organization 
                        that the Secretary determines is appropriate 
                        for purposes of this subclause.
                            ``(bb) Has such other training or 
                        experience as the Secretary determines will 
                        demonstrate the ability of the nurse 
                        practitioner or physician assistant to treat 
                        and manage opiate-dependent patients.
                    ``(III) The nurse practitioner or physician 
                assistant is supervised by or works in collaboration 
                with a qualifying physician, if the nurse practitioner 
                or physician assistant is required by State law to 
                prescribe medications for the treatment of opioid use 
                disorder in collaboration with or under the supervision 
                of a physician.
        The Secretary may review and update the requirements for being 
        a qualifying other practitioner under this clause.''; and
            (4) in subparagraph (H)--
                    (A) in clause (i), by inserting after subclause 
                (II) the following:
            ``(III) Such other elements of the requirements under this 
        paragraph as the Secretary determines necessary for purposes of 
        implementing such requirements.''; and
                    (B) by amending clause (ii) to read as follows:
    ``(ii) Not later than 1 year after the date of enactment of the 
Opioid Use Disorder Treatment Expansion and Modernization Act, the 
Secretary shall update the treatment improvement protocol containing 
best practice guidelines for the treatment of opioid-dependent patients 
in office-based settings. The Secretary shall update such protocol in 
consultation with experts in opioid use disorder research and 
treatment.''.
    (b) Recommendation of Revocation or Suspension of Registration in 
Case of Substantial Noncompliance.--The Secretary of Health and Human 
Services may recommend to the Attorney General that the registration of 
a practitioner be revoked or suspended if the Secretary determines, 
according to such criteria as the Secretary establishes by regulation, 
that a practitioner who is registered under section 303(g)(2) of the 
Controlled Substances Act (21 U.S.C. 823(g)(2)) is not in substantial 
compliance with the requirements of such section, as amended by this 
Act.
    (c) Opioid Defined.--Section 102(18) of the Controlled Substances 
Act (21 U.S.C. 802(18)) is amended by inserting ``or `opioid''' after 
``The term `opiate'''.
    (d) Reports to Congress.--
            (1) In general.--Not later than 2 years after the date of 
        enactment of this Act and not less than over every 5 years 
        thereafter, the Secretary of Health and Human Services, in 
        consultation with the Drug Enforcement Administration and 
        experts in opioid use disorder research and treatment, shall--
                    (A) perform a thorough review of the provision of 
                opioid use disorder treatment services in the United 
                States, including services provided in opioid treatment 
                programs and other specialty and nonspecialty settings; 
                and
                    (B) submit a report to the Congress on the findings 
                and conclusions of such review.
            (2) Contents.--Each report under paragraph (1) shall 
        include an assessment of--
                    (A) compliance with the requirements of section 
                303(g)(2) of the Controlled Substances Act (21 U.S.C. 
                823(g)(2)), as amended by this Act;
                    (B) the measures taken by the Secretary of Health 
                and Human Services to ensure such compliance;
                    (C) whether there is further need to increase or 
                decrease the number of patients a waivered practitioner 
                is permitted to treat, as provided for by the amendment 
                made by subsection (a)(1);
                    (D) the extent to which, and proportions with 
                which, the full range of Food and Drug Administration-
                approved treatments for opioid use disorder are used in 
                routine health care settings and specialty substance 
                use disorder treatment settings;
                    (E) access to, and use of, counseling and recovery 
                support services, including the percentage of patients 
                receiving such services;
                    (F) changes in State or local policies and 
                legislation relating to opioid use disorder treatment;
                    (G) the use of prescription drug monitoring 
                programs by practitioners who are permitted to dispense 
                narcotic drugs to individuals pursuant to a waiver 
                under section 303(g)(2) of the Controlled Substances 
                Act (21 U.S.C. 823(g)(2));
                    (H) the findings resulting from inspections by the 
                Drug Enforcement Administration of practitioners 
                described in subparagraph (G); and
                    (I) the effectiveness of cross-agency collaboration 
                between Department of Health and Human Services and the 
                Drug Enforcement Administration for expanding effective 
                opioid use disorder treatment.

SEC. 4. SENSE OF CONGRESS.

    It is the Sense of Congress that, with respect to the total number 
of patients that a qualifying physician (as defined in subparagraph 
(G)(iii) of section 303(g)(2) of the Controlled Substances Act (21 
U.S.C. 823(g)(2)) can treat at any one time pursuant to such section, 
the Secretary of Health and Human Services should consider raising such 
total number to 250 patients following a third notification to the 
Secretary of the need and intent of the physician to treat up to 250 
patients that is submitted to the Secretary not sooner than 1 year 
after the date on which the physician submitted to the Secretary a 
second notification to treat up to 100 patients.

SEC. 5. PARTIAL FILLS OF SCHEDULE II CONTROLLED SUBSTANCES.

    (a) In General.--Section 309 of the Controlled Substances Act (21 
U.S.C. 829) is amended by adding at the end the following:
    ``(f) Partial Fills of Schedule II Controlled Substances.--
            ``(1) Partial fills.--
                    ``(A) In general.--A prescription for a controlled 
                substance in schedule II may be partially filled if--
                            ``(i) it is not prohibited by State law;
                            ``(ii) the prescription is written and 
                        filled in accordance with the Controlled 
                        Substances Act (21 U.S.C. 801 et seq.), 
                        regulations prescribed by the Attorney General, 
                        and State law;
                            ``(iii) the partial fill is requested by 
                        the patient or the practitioner that wrote the 
                        prescription; and
                            ``(iv) the total quantity dispensed in all 
                        partial fillings does not exceed the total 
                        quantity prescribed.
                    ``(B) Other circumstances.--A prescription for a 
                controlled substance in schedule II may be partially 
                filled in accordance with section 1306.13 of title 21, 
                Code of Federal Regulations (as in effect on the date 
                of enactment of the Reducing Unused Medications Act of 
                2016).
            ``(2) Remaining portions.--
                    ``(A) In general.--Except as provided in 
                subparagraph (B), remaining portions of a partially 
                filled prescription for a controlled substance in 
                schedule II--
                            ``(i) may be filled; and
                            ``(ii) shall be filled not later than 30 
                        days after the date on which the prescription 
                        is written.
                    ``(B) Emergency situations.--In emergency 
                situations, as described in subsection (a), the 
                remaining portions of a partially filled prescription 
                for a controlled substance in schedule II--
                            ``(i) may be filled; and
                            ``(ii) shall be filled not later than 72 
                        hours after the prescription is issued.''.
    (b) Rule of Construction.--Nothing in this section shall be 
construed to affect the authority of the Attorney General to allow a 
prescription for a controlled substance in schedule III, IV, or V of 
section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) to 
be partially filled.

            Passed the House of Representatives May 11, 2016.

            Attest:

                                                 KAREN L. HAAS,

                                                                 Clerk.

Ex Output:
Opioid Use Disorder Treatment Expansion and Modernization Act (Sec. 3) This bill amends the Controlled Substances Act to revise the requirements for a practitioner to administer, dispense, or prescribe narcotic drugs for maintenance or detoxification treatment in an office-based opioid treatment program. Currently, a practitioner must notify the Department of Health and Human Services (HHS) and certify that he or she is a qualifying physician (i.e., a state-licensed physician with certain expertise), has the capacity to refer patients for appropriate counseling and ancillary services, and will comply with a patient limit. The patient limit is how many patients the practitioner can treat under the office-based treatment program at one time. This legislation expands qualifying practitioners to include nurse practitioners and physician assistants who are licensed in a state, have expertise (such as relevant training or expertise), and prescribe medications for opioid use disorder in collaboration with or under the supervision of a qualifying physician if state law requires physician oversight of prescribing authority. Additionally, it requires a qualifying practitioner to also certify that he or she will comply with reporting requirements and has the capacity to provide directly or by referral, or in another manner prescribed by HHS, all drugs approved by the Food and Drug Administration to treat opioid use disorder. HHS may issue regulations to change the maximum patient limit for a qualifying practitioner. If HHS increases the limit, then a qualifying practitioner must additionally certify that he or she will obtain written consent from each patient regarding available treatment options. HHS must update the treatment improvement protocol containing best practice guidelines for the treatment of opioid-dependent patients in office-based settings. HHS may recommend revoking or suspending the registration of a practitioner who fails to comply with the requirements of this Act. (Sec. 4) The bill expresses the sense of Congress that HHS should consider raising from 100 to 250 the maximum patient limit for a qualifying physician. (Sec. 5) It amends the Controlled Substances Act to allow a pharmacist to partially fill a prescription for a schedule II controlled substance (such as a prescription opioid painkiller) if: (1) it is not prohibited by state law, (2) it is prescribed in accordance with existing laws and regulations, (3) it is requested by the patient or prescribing practitioner, and (4) the total quantity dispensed in partial fillings does not exceed the total quantity prescribed. Additionally, a pharmacist may partially fill a prescription for a schedule II controlled substance in other circumstances in accordance with existing Drug Enforcement Administration (DEA) regulations. (Current DEA regulations permit partial fills when a pharmacist cannot supply a full quantity, a patient resides in a long-term care facility, or a patient is terminally ill.) The remaining of a partially filled prescription may be filled within 30 days or, in the case of an emergency situation, within 72 hours.


Ex Input:
SECTION 1. NEXT GENERATION LIGHTING INITIATIVE.

    (a) Definitions.--In this section:
            (1) Consortium.--The term ``consortium'' means the 
        consortium selected by the Secretary under subsection (d)(1).
            (2) Initiative.--The term ``Initiative'' means the Next 
        Generation Lighting Initiative carried out under subsection 
        (b).
            (3) Secretary.--The term ``Secretary'' means the Secretary 
        of Energy.
    (b) General Authority.--The Secretary shall carry out a program, to 
be known as the ``Next Generation Lighting Initiative'', to support 
research, development, demonstration, and commercial application 
activities related to advanced solid-state lighting technologies based 
on white light emitting diodes.
    (c) Objectives.--The objectives of the Initiative shall be--
            (1) to develop, by 2012, advanced solid-state lighting 
        technologies based on white light emitting diodes that, 
        compared to incandescent and fluorescent lighting technologies, 
        are--
                    (A) longer lasting;
                    (B) more energy-efficient; and
                    (C) cost-competitive;
            (2) to develop an inorganic white light emitting diode that 
        has an efficiency of 160 lumens per watt and a 10-year 
        lifetime; and
            (3) to develop an organic white light emitting diode with 
        an efficiency of 100 lumens per watt with a 5-year lifetime 
        that--
                    (A) illuminates over a full color spectrum;
                    (B) covers large areas over flexible surfaces; and
                    (C) does not contain harmful pollutants (such as 
                mercury) that are typical of fluorescent lamps.
    (d) Fundamental Research.--
            (1) Consortium.--The Secretary shall carry out the 
        fundamental research activities of the Initiative through a 
        private consortium (which may include private firms, trade 
        associations and institutions of higher education), which the 
        Secretary shall select through a competitive process.
            (2) Submission of information.--Each proposed consortium 
        shall submit to the Secretary such information as the Secretary 
        may require, including a program plan agreed to by all 
        participants of the consortium.
            (3) Joint venture.--The consortium shall be structured as a 
        joint venture among the participants of the consortium.
            (4) Governing council.--The Secretary shall serve on the 
        governing council of the consortium.
            (5) Eligibility.--To be eligible for a grant under 
        paragraph (6), an applicant shall be broadly representative of 
        United States solid-state lighting research, development, and 
        manufacturing expertise.
            (6) Grants.--
                    (A) In general.--The Secretary shall award grants 
                for fundamental research to the consortium, which the 
                consortium may disburse to researchers, including 
                researchers that are not participants in the 
                consortium.
                    (B) Submission.--To receive a grant, the consortium 
                shall submit to the Secretary a description of the 
                proposed research and a list of the persons that will 
                receive funding.
                    (C) Cost-sharing.--Grants shall be matched by the 
                consortium in accordance with subsection (h).
            (7) National laboratories.--National Laboratories may 
        participate in the research under this section and receive 
        funds from the consortium.
            (8) Intellectual property.--Participants in the consortium 
        and the Federal Government shall have royalty-free nonexclusive 
        rights to use intellectual property derived from research 
        funded under this subsection.
    (e) Development, Demonstration, and Commercial Application.--
            (1) In general.--The Secretary shall carry out the 
        development, demonstration, and commercial application 
        activities of the Initiative through awards to private firms, 
        trade associations, and institutions of higher education.
            (2) Preference.--In selecting awardees, the Secretary shall 
        give preference to members of the consortium.
    (f) Plans and Assessments.--
            (1) In general.--The consortium shall formulate an annual 
        operating plan which shall include research priorities, 
        technical milestones, and plans for technology transfer, and 
        which shall be subject to approval by the Secretary.
            (2) Review.--
                    (A) In general.--The Secretary shall enter into an 
                arrangement with the National Academy of Sciences to 
                conduct periodic reviews of the Initiative.
                    (B) Duties.--The Academy shall review the research 
                priorities, technical milestones, and plans for 
                technology transfer established under paragraph (1) and 
                evaluate the progress toward achieving them.
                    (C) Consideration of results.--The Secretary shall 
                consider the results of the reviews in evaluating the 
                plans submitted under paragraph (1).
    (g) Audit.--
            (1) In general.--The Secretary shall retain an independent, 
        commercial auditor to perform an audit of the consortium to 
        determine the extent to which the funds authorized by this 
        section have been expended in a manner consistent with this 
        section.
            (2) Report.--
                    (A) To the secretary.--The auditor shall annually 
                submit to the Secretary a report describing the results 
                of the audit under paragraph (1).
                    (B) To congress.--The Secretary shall transmit to 
                Congress a copy of each report submitted under 
                subparagraph (A), including a plan to remedy any 
                deficiencies noted in the report.
    (h) Cost Sharing.--
            (1) Research and development.--
                    (A) In general.--For research and development 
                programs carried out under this section, the Secretary 
                shall require a commitment from non-Federal sources of 
                at least 20 percent of the cost of the project.
                    (B) Reduction or waiver.--The Secretary may reduce 
                or waive the non-Federal requirement under this 
                subsection if the Secretary determines that the 
                research and development is of a basic or fundamental 
                nature.
            (2) Demonstration and commercial application.--
                    (A) In general.--The Secretary shall require at 
                least 50 percent of the costs directly and specifically 
                related to any demonstration or commercial application 
                project under this section to be provided from non-
                Federal sources.
                    (B) Reduction.--The Secretary may reduce the non-
                Federal requirement under this subsection if the 
                Secretary determines that the reduction is necessary 
                and appropriate considering the technological risks 
                involved in the project and is necessary to meet the 
                objectives of this title.
            (3) Calculation of amount.--In calculating the amount of 
        the non-Federal commitment under paragraph (1) or (2), the 
        Secretary may include personnel, services, equipment, and other 
        resources.
    (i) Authorization of Appropriations.--There are authorized to be 
appropriated to carry out this section--
            (1) $10,000,000 for fiscal year 2004; and
            (2) $50,000,000 for each of fiscal years 2005 through 2013.
    (j) Termination of Initiative.--The Secretary shall terminate the 
Initiative not later than September 30, 2013.

Ex Output:

Next Generation Lighting Initiative Act - Directs the Secretary of Energy to implement: (1) the Next Generation Lighting Initiative to support research, development, demonstration, and commercial application activities related to advanced solid-state lighting technologies based on white light emitting diodes; (2) fundamental research activities of the Initiative through a private consortium (which may include private firms, trade associations and institutions of higher education), selected through a competitive process; and (3) development, demonstration, and commercial application activities of the Initiative through awards to private firms, trade associations, and institutions of higher education.